Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention
about
Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized TrialDrug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.Influence of Chitosan Swelling Behaviour on Controlled Release of Tenofovir from Mucoadhesive Vaginal Systems for Prevention of Sexual Transmission of HIV.The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
P2860
Q33821090-B8689E8E-A757-41F4-97B9-75BA558B77DAQ36166932-93A773E1-7989-492C-8E56-79442D144451Q36934918-FB5FE645-444F-4ABA-B7AE-0D45A1F93D20Q37023114-646B5F73-8F79-4D99-A08B-4D154D4FCE7FQ37358616-C8C09E05-A270-47C2-BCB7-6D1428331119Q37678318-2FAADDBE-80A3-49CB-9F30-865A85DC7B5EQ38641903-9E43FF70-F943-4BE8-B356-F19EEA306FFDQ40086722-93884855-4DCF-4DAA-8527-5D9B1F9E960FQ53681301-8DC54A58-725C-405C-A6A5-9E75061EAD19Q55338133-BDB05898-4E03-4451-B428-EF8FDB1C5D13Q58787428-2D003C02-C664-4FBC-938F-508004EB3D72
P2860
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@ast
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@en
type
label
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@ast
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@en
prefLabel
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@ast
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@en
P2093
P2860
P1476
Formulation and characterizati ...... rals (ARVs) for HIV prevention
@en
P2093
Ayman Akil
Bernard J Moncla
Brid Devlin
Hrushikesh Agashe
Kevin Uranker
Lisa Cencia Rohan
Sharon L Hillier
P2860
P304
P356
10.1007/S11095-014-1474-4
P577
2014-07-31T00:00:00Z